悦康药业(688658) - 2022 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2022 reached ¥1,573,105,309.87, an increase of 29.60% year-over-year[8] - Net profit attributable to shareholders was ¥195,204,855.01, up 21.54% compared to the same period last year[8] - Total operating revenue for the first three quarters of 2022 reached ¥3,502,028,882.01, an increase of 4.68% compared to ¥3,345,210,497.61 in the same period of 2021[20] - Net profit for the first three quarters of 2022 was ¥337,783,347.02, a decrease of 9.27% from ¥372,438,690.81 in the same period last year[21] - The company reported a profit before tax of ¥382,616,542.36, down from ¥423,859,470.54 in the previous year, indicating a decline of 9.73%[21] Research and Development - R&D expenses totaled ¥109,084,572.55, representing a significant increase of 146.41% year-over-year[9] - The proportion of R&D expenses to revenue was 6.93%, an increase of 3.28 percentage points from the previous year[9] - Research and development expenses surged to ¥261,847,416.32, a significant increase of 164.5% compared to ¥98,871,475.74 in 2021[21] - The company plans to continue investing in R&D to enhance product offerings and market competitiveness[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,036,344,691.43, a 5.41% increase from the end of the previous year[9] - The total equity attributable to shareholders was ¥4,016,696,168.86, a 2.37% increase from the previous year[9] - Total liabilities increased to ¥2,012,250,438.07, compared to ¥1,799,673,767.06 in the previous year, reflecting a growth of 11.79%[20] - Current liabilities totaled approximately CNY 1.89 billion, up from CNY 1.68 billion, reflecting an increase of about 12.4%[19] - The total non-current assets reached approximately CNY 1.97 billion, an increase from CNY 1.66 billion, representing a growth of about 18.5%[19] Cash Flow - The company reported a net cash flow from operating activities of -¥17,933,153.46 for the year-to-date period[9] - The net cash flow from operating activities was -17,933,153.46, a significant decrease compared to 284,815,436.92 from the previous period[23] - Total cash inflow from operating activities was 3,315,838,808.93, while cash outflow was 3,333,771,962.39, resulting in a net cash flow of -17,933,153.46[23] - Cash inflow from investment activities was 63,890.00, with cash outflow totaling 514,029,681.38, leading to a net cash flow of -513,965,791.38[23] - Cash inflow from financing activities was 110,000,000.00, while cash outflow was 326,604,892.99, resulting in a net cash flow of -216,604,892.99[24] Other Financial Metrics - Basic earnings per share for the period were ¥0.43, reflecting a 19.44% increase year-over-year[9] - Earnings per share (EPS) for the first three quarters of 2022 was ¥0.75, down from ¥0.83 in 2021[22] - The company confirmed a share-based payment expense of ¥55,840,200.00 during the reporting period, affecting profit margins significantly[9] - The company received 15,487,034.63 in tax refunds, an increase from 4,631,448.62 in the previous period[23] - The company paid 306,538,734.72 in dividends and interest, compared to 204,621,081.43 in the previous period[24] Changes in Financial Position - The company's cash and cash equivalents decreased to approximately CNY 1.73 billion from CNY 2.44 billion, representing a decline of about 29%[18] - Accounts receivable increased significantly to approximately CNY 1.25 billion, up from CNY 816.81 million, marking an increase of approximately 53%[18] - Inventory levels rose to approximately CNY 746.55 million, compared to CNY 632.31 million, indicating an increase of about 18%[18] - The company reported a significant increase in employee compensation payments, totaling 330,632,595.38 compared to 244,752,646.11 previously[23] - The impact of exchange rate changes on cash and cash equivalents was 4,851,237.71, contrasting with -40,873.13 in the previous period[24] Corporate Developments - The company has not reported any significant new product launches or technological advancements during the reporting period[17] - There are no significant mergers or acquisitions reported in the current financial period[17]